UBS Group
RYTM icon

UBS Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

UBS Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,100
Closed -$429K – 10763
2025
Q1 		$429K Buy
+8,100
New +$449K ﹤0.01% 5968

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

UBS Group's RYTM Position: Q1 2026 in Review

UBS Group reduced its Rhythm Pharmaceuticals (RYTM) stake by 46% in Q1 2026, selling an estimated $19M and leaving 231,650 shares worth $20.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2576.

UBS Group first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $45.7M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • UBS Group held 231,650 shares of Rhythm Pharmaceuticals worth $20.1M as of Q1 2026.
  • UBS Group sold 195,586 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $19M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2576 holding.
  • UBS Group first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • UBS Group's Rhythm Pharmaceuticals position peaked at $45.7M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.